Free Trial

FY2026 Earnings Estimate for Savara Issued By HC Wainwright

Savara logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright forecasts Savara will lose $0.65 per share in FY2026, slightly less than the $0.68 consensus loss. Its estimates project the company reaching profitability in FY2029, with earnings of $0.13 per share.
  • HC Wainwright maintained a Buy rating and $10 price target. Overall, analysts have a “Moderate Buy” consensus rating and an average target of $10.29, though one analyst rates the stock Sell.
  • Savara reported a quarterly loss of $0.17 per share, beating the $0.18 loss analysts expected by one cent.
  • Five stocks we like better than Savara.

Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Savara in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.65) per share for the year. HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Savara's current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Savara's Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $0.13 EPS and FY2030 earnings at $0.32 EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research report on Thursday, October 15th. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research report on Sunday, October 4th. JPMorgan Chase & Co. initiated coverage on shares of Savara in a research note on Wednesday, October 7th. They set an "overweight" rating and a $12.00 price target on the stock. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Savara in a research note on Wednesday, October 7th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.29.

Get Our Latest Report on Savara

Savara Stock Performance

NASDAQ:SVRA opened at $4.64 on Monday. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -7.61 and a beta of 0.32. Savara has a 1 year low of $4.13 and a 1 year high of $7.01. The stock's 50 day simple moving average is $4.93 and its two-hundred day simple moving average is $5.34. The company has a debt-to-equity ratio of 0.28, a current ratio of 8.55 and a quick ratio of 8.55.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01.

Institutional Investors Weigh In On Savara

Several large investors have recently added to or reduced their stakes in SVRA. Renaissance Technologies LLC raised its holdings in Savara by 96.5% during the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company's stock valued at $3,564,000 after buying an additional 320,572 shares during the period. Walleye Capital LLC purchased a new position in Savara during the second quarter worth $1,532,000. BlackRock Inc. purchased a new position in Savara during the second quarter worth $76,966,000. Nantahala Capital Management LLC purchased a new position in Savara during the second quarter worth $42,977,150. Finally, Deutsche Bank AG bought a new position in Savara during the second quarter valued at $5,328,000. 87.93% of the stock is owned by institutional investors.

About Savara

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Further Reading

Earnings History and Estimates for Savara (NASDAQ:SVRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Savara Right Now?

Before you consider Savara, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.

While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines